Evaluation of P-glycoprotein expression in feline lymphoma and correlation with clinical outcome

Veterinary and Comparative Oncology

Volumn 6, Issue 3, 2008, Pages 201-211

  Brenn, S H ^a,b   Couto, S S ^a,c   Craft, D M ^a   Leung, C ^a   Bergman, P J ^a,d  

^a ANIMAL MEDICAL CENTER   (United States)

^b Oradell Animal Hospital   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BrightHeart Veterinary Centers   (United States)

Author keywords

Chemotherapy; Drug resistance; Feline; Lymphosarcoma; MDR

Indexed keywords

FELIDAE;

GLYCOPROTEIN P; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CAT; CAT DISEASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA; MALE; METABOLISM; PHYSIOLOGY; PROGNOSIS;

ANIMALS; CAT DISEASES; CATS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOMA; MALE; P-GLYCOPROTEIN; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 63849134753     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2008.00161.x     Document Type: Article

References (38)

1. Hardy WD Jr. Hematopoietic tumors of cats. Journal of the American Animal Hospital Association 1981; 17: 921-940.
2. Milner RJ, Peyton J, Cooke K, Fox Le, Gallagher A, Gordon P and Hester J. Response rates and survival times for cats with lymphoma treated with the University of Wisconsin-Madison chemotherapy protocol: 38 cases (1996-2003). Journal of the American Veterinary Medical Association 2005; 227: 1118-1122.
3. Teske E, van Straten G, van Noort R and Rutteman GR. Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: New results with an old protocol. Journal of Veterinary Internal Medicine 2002; 16: 179-186.
4. Bergman PJ, Ogilvie GK and Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine 1996; 10: 354-359.
5. Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Veterinary Pathology 1996; 33: 533-541.
6. Moore AS, Leveille CR, Reimann KA, Shu H and Arias IM. The Expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Investigation 1995; 13: 475-479.
7. Lee JJ, Hughes CS, Fine RL and Page RL. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996; 77: 1892-1898.
8. Bergman PJ. Mechanisms of anticancer drug resistance. Veterinary Clinics of North American Small Animal Practice 2003; 33: 651-657.
9. Okai Y, Nakamura N, Matsushiro H, Kato H, Setoguchi A, Yazawa M, Okuda M, Watari T, Hasegawa A and Tsujimoto H. Molecular analysis of multidrug resistance in feline lymphoma cells. American Journal of Veterinary Research 2000; 61: 1122-1127.
10. Gabor LJ, Canfield PJ and Malik R. Immunophenotypic and histological characterisation of 109 cases of feline lymphosarcoma. Australian Veterinary Journal 1999; 77: 436-441.
11. Patterson-Kane JC, Kugler BP and Francis K. The possible prognostic significance of immunophenotype in feline alimentary lymphoma: A pilot study. Journal of Comparative Pathology 2004; 130: 220-222.
12. Affolter VK and Moore PF. Feline progressive histiocytosis. Veterinary Pathology 2006; 43: 646-655.
13. Winston J, Craft DM, Scase TJ and Bergman PJ. Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Veterinary Comparative Oncology 2005; 3: 1-8.
14. Vail DM, Kisseberth WC, Obradovich JE, Moore, FM, London CA, MacEwen EG and Ritter MA. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Experimental Hematology 1996; 24: 807-815.
15. Rassnick KM, Mauldin GN, Moroff SD, Mauldin, GE, McEntee MC and Mooney SC. Prognostic value of argyrophilic nucleolar organizer region (AgNOR) staining in feline intestinal lymphoma. Journal of Veterinary Internal Medicine 1999; 13: 187-190.
16. Vail DM, Moore AS, Ogilvie GK and Volk LM. Feline lymphoma (145 cases): proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. Journal of Veterinary Internal Medicine 1998; 12: 349-354.
17. Vail DM. Feline lymphoma and leukemia. In: Small Animal Clinical Oncology, 4th edn., SJ Withrow and DM Vail, eds., Canada, Saunders Elsevier, 2007: 733-756.
18. Slawienski MJ, Mauldin GE, Mauldin GN and Patnaik AK. Malignant colonic neoplasia in cats: 46 cases. Journal of the American Veterinary Medical Association 1997; 211: 878-881.
19. Cole SPC, Tannock IF. Drug resistance. In: The Basic Science of Oncology, 4th edn., IF Tannock, RP Hill, RG Briston and L Harrington, eds., New York, McGraw Hill Medical Publishing Division, 2005: 376-399.
20. Ramos-Vara JA. Technical aspects of immunohistochemistry. Veterinary Pathology 2005; 42: 405-426.
21. Vail DM, MacEwen EG. Feline lymphoma and leukemias. In: Small Animal Clinical Oncology, 3rd edn., SJ Withrow and EG MacEwen, eds., Philadelphia, WB Saunders, 2001: 590-611.
22. Louwerens M, London CA, Pedersen NC and Lyons LA. Feline lymphoma in the post-feline leukemia virus era. Journal of Veterinary Internal Medicine 2005; 19: 329-335.
23. Kristal O, Lana SE, Ogilvie GK, Rand WM, Cotter SM and Moore AS. Single agent chemotherapy with doxorubicin for feline lymphoma: A retrospective study of 19 cases (1994-1997). Journal of Veterinary Internal Medicine 2001; 15: 125-130.
24. Mahony OM, Moore AS, Cotter SM, Engler SJ, Brown D and Penninck DG. Alimentary lymphoma in cats: 28 cases (1988-1993). Journal of the American Veterinary Medical Association 1995; 207: 1593-1598.
25. Mooney SC, Hayes AA, MacEwen EG, Matus RE, Geary A and Shurgoy BA. Treatment and prognostic factors in lymphoma in cats: 103 cases (1977-1981). Journal of the American Veterinary Medical Association 1989; 194: 696-699.
26. Dobson JM, Blackwood LB, McInnes EF, Bostock DE, Nicholas P, Hoather TM and Tom BD. Prognostic variables in canine multicentric lymphosarcoma. Journal of Small Animal Practice 2001; 42: 377-384.
27. Ruslander DA, Gebhard DH, Tompkins MB, Grindem CB and Page RL. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 1997; 11: 169-172.
28. Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. Journal of the American Veterinary Medical Association 1994; 205: 1722-1728.
29. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Horvitz AI and Lieberman PH. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990; 66: 480-490.
30. Bostock DE, Crocker J, Harris K and Smith P. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumors. British Journal of Cancer 1989; 59: 915-918.
31. Korkolopoulou P, Patsouris E, Pangalis G, Tsenga A, Elemenoglou J, Thomas-Tsangli E, Spandidos D and Kittas C. A comparative assessment of proliferating cell nuclear antigen, c-myc p62, and nucleolar organizer region staining in non-Hodgkin's lymphomas: A histochemical and immunohistochemical study of 200 cases. Human Pathology 1993; 24: 371-377.
32. Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant lymphoma. Veterinary Pathology 1999; 36: 292-300.
33. Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone, II: Treatment of cats. Journal of the American Animal Hospital Association 1983; 19: 166-172.
34. Elmslie RE, Ogilvie GK, Gillette EL and McChesney-Gillette S. Radiotherapy with and without chemotherapy for localized lymphoma in 10 cats. Veterinary Radiology 1991; 32: 277-280.
35. Price GS, Frazier DL. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. Journal of Veterinary Internal Medicine 1998; 12: 267-271.
36. Chu E, DeVita VT. Principles of cancer management: Chemotherapy. In: Cancer: Principles and Practice of Oncology, 7th edn., VT DeVita, S Hellman and SA Rosenberg, eds., Philadelphia, Lippincott, Williams and Wilkins, 2004: 289-306.
37. Vail DM, MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In: Small Animal Clinical Oncology, 3rd edn., SJ Withrow and EG MacEwen, eds., Philadelphia, WB Saunders Co., 2001: 558-590.
38. Fukushima K, Okai Y, Matsuura S, Tsujimoto H and Endo Y. Molecular cloning of feline lung resistance-related protein (LRP) cDNA and its expression in a feline lymphoma cell line and adriamycin-resistant subline. Journal of Veterinary Medical Science 2006; 68: 885-890.